OpenScience.ink

2 days ago • JCEM case reports

Postmenopausal bleeding linked to semaglutide poses a diagnosis challengePostmenopausal bleeding associated with semaglutide: a diagnostic challenge.

Case Reports

3 days ago • BMC endocrine disorders

Effectiveness and safety of 12 mg versus 36 mg orforglipron doses for maintaining weight in people with obesity, with or without diabetesEfficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.

📖 Top 20% JournalSystematic Review

3 days ago • Frontiers in endocrinology

Added benefits of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone for type 2 diabetes and fatty liver disease in Asian populationsIncremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis.

🎖️ Top 10% JournalSystematic Review

3 days ago • Mayo Clinic proceedings. Digital health

Body Weight and Blood Pressure Changes After Starting a Glucagon-Like Peptide 1 Drug: Analysis Using Data from Linked DevicesReal-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data.

📖 Top 50% JournalArticle

3 days ago • Zentralblatt fur Chirurgie

Uses and Side Effects of GLP-1 Receptor Drugs in Urinary and Male Reproductive Health[GLP-1 Receptor Agonists in Urology and Andrology: Indications, Opportunities and Clinically Relevant Adverse Effects].

English Abstract

3 days ago • Bioorganic chemistry

Deoxycalyxin A lowers blood sugar by activating TGR5 to increase GLP-1 through a specific signaling pathwayDeoxycalyxin A exerts hypoglycemic effects through activating TGR5-induced GLP-1 secretion via TGR5/PKA/MEK/ERK pathway.

📖 Top 30% JournalArticle

3 days ago • Anaesthesia

Use of glucagon-like peptide-1 receptor drugs around surgery and patient outcomes in a national studyPeri-operative glucagon-like peptide-1 receptor agonist use and outcomes: a national prospective multicentre cohort study.

🥉 Top 5% JournalArticle

3 days ago • Nature metabolism

Combination of cagrilintide and retatrutide improves weight loss and metabolism in obese male ratsCagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.

🥇 Top 1% JournalArticle

3 days ago • American journal of respiratory and critical care medicine

GLP-1 receptor drugs and their ability to prevent sleep apnea in people with type 2 diabetesEffectiveness of GLP-1 receptor agonists to prevent obstructive sleep apnea in patients with type 2 diabetes: active comparator, new user cohort study.

🥇 Top 1% JournalArticle

3 days ago • Lung

How GLP-1 Receptor Agonists May Help Pulmonary Hypertension: Mechanisms, Animal Studies, and Unknowns in Human TreatmentGLP-1 Receptor Agonists in Pulmonary Hypertension: Mechanistic Rationale, Preclinical Evidence, and Clinical Knowledge Gaps.

Article

3 days ago • JAMA cardiology

Semaglutide’s effectiveness and safety in people with different levels of frailtyEfficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.

🥇 Top 1% JournalArticle

3 days ago • Diabetes care

How India Makes New Diabetes Medicines Affordable and Available for Other CountriesMaking Modern Diabetes Medications Affordable and Accessible: Lessons From India for Other Countries.

Article

3 days ago • Rapid communications in mass spectrometry : RCM

Tracking Retatrutide Levels in Human Blood and Urine for Anti-Doping TestsDetection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.

📖 Top 50% JournalArticle

3 days ago • Journal of psychopharmacology (Oxford, England)

Adding GLP-1 receptor drugs to reduce heart and metabolism risks in patients taking antipsychotics: A review of clinical trialsAdjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.

Article

3 days ago • Cureus

The Increasing Influence of Oral GLP-1 Drugs on UK Obesity PoliciesAssessing the Growing Impact of Oral GLP-1 Agonists on National Obesity Policies of the United Kingdom.

Editorial

3 days ago • Clinics in dermatology

The history of diabetes drugs inspired by Gila monster venom and their use in skin treatmentFrom Gila Monster Venom to Dermatology: The History of GLP-1 Receptor Agonists.

📖 Top 50% JournalArticle

3 days ago • Journal of gastrointestinal cancer

Long-Term Use of GLP-1 Receptor Agonists and Risk of Developing Pancreatic CancerLong-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score-Matched Retrospective Cohort Study Using the TriNetX Network.

📖 Top 50% JournalArticle

3 days ago • Endocrinology, diabetes & metabolism

Comparing the Effects of Semaglutide, Liraglutide, and Tirzepatide on Heart and Metabolic HealthImpact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review.

📖 Top 20% JournalComparative Study

3 days ago • Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

Obesity, hormone-based diabetes treatments, and heart disease in womenObesity, incretin-based therapies, and cardiovascular disease in women.

📖 Top 30% JournalArticle

4 days ago • Biology

Combined Exendin-4 and Rituximab Treatment Improves Insulin-Producing Cell Function and Slows Diabetes Progression in NOD MiceCombined Exendin-4 and Rituximab Treatment Improves β-Cell Function and Delays Disease Progression in NOD Mice.

📖 Top 20% JournalArticle

4 days ago • Nutrients

Using Lifestyle Changes with Incretin-Based Weight Loss Drugs: Combining Exercise, Diet, and Behavior for Lasting ResultsLifestyle Medicine as Co-Therapy During Incretin-Based Anti-Obesity Pharmacotherapy: Integrating Physical Activity, Nutrition, and Behavioral Strategies for Long-Term Success.

🎖️ Top 10% JournalArticle

4 days ago • Nutrients

Hidden Malnutrition in the GLP-1 Treatment Era: Micronutrient Levels, Protein Intake, and Muscle Mass as Important Nutritional FactorsHidden Malnutrition in the GLP-1 Era: Micronutrient Status, Protein Adequacy, and Lean Mass as Emerging Nutritional Considerations-A Narrative Review.

🎖️ Top 10% JournalArticle

4 days ago • Frontiers in pharmacology

New advances and challenges in treating fatty liver disease linked to metabolism problemsA new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.

📖 Top 20% JournalArticle

4 days ago • World psychiatry : official journal of the World Psychiatric Association (WPA)

Agreed clinical and research guidelines for using glucagon-like peptide-1 receptor drugs in treating eating disordersConsensus-based clinical and research recommendations for use of glucagon-like peptide-1 receptor agonists in the context of eating disorders: a modified Delphi study.

🏆 Top 0.1% JournalArticle

4 days ago • Cells

🎖️ Top 10% JournalArticle

4 days ago • Frontiers in endocrinology

Changes in blood sugar control and weight in obese and non-obese adults with type 2 diabetes treated with SGLT-2 inhibitors or GLP-1 receptor agonistsComparative change in HbA1c and weight outcomes between obese and non-obese adults with type 2 diabetes mellitus treated with SGLT-2 inhibitors or GLP-1 receptor agonists.

🎖️ Top 10% JournalMulticenter Study

4 days ago • Frontiers in medicine

Glucagon-like peptide-1 receptor drugs and tirzepatide linked to lower death, heart, and mental health risks in people with hidradenitis suppurativa and type 2 diabetes or obesityGlucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study.

📖 Top 20% JournalArticle

4 days ago • Cureus

Semaglutide use and mood disorders in women with multiple hormonal and metabolic problemsInvestigating the Association Between Semaglutide Use and Mood Disorders in Polyendocrine Metabolic Ovarian Syndrome: A Retrospective Cohort Study.

Article

4 days ago • Journal of clinical medicine

How GLP-1 Medicines Affect Body Fat and Muscle in People with Overweight and ObesityThe Impact of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists on Body Composition in Individuals with Overweight and Obesity: A Systematic Review and Meta-Analysis.

📖 Top 20% JournalArticle

4 days ago • Medicinal chemistry (Shariqah (United Arab Emirates))

Using Computer Design to Create New Oral Drugs for DiabetesComputer-Aided Design of Novel Acrylamido Derivatives as Potential Oral Antidiabetic Agents.

📖 Top 50% JournalArticle

← prevpage 2 of 14next →

Latest GLP-1 Therapies Research Papers